160 related articles for article (PubMed ID: 31239542)
21. CXCR4 receptor blockage reduces the contribution of tumor and stromal cells to the metastatic growth in the liver.
Benedicto A; Romayor I; Arteta B
Oncol Rep; 2018 Apr; 39(4):2022-2030. PubMed ID: 29436696
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of stromal CXCR4 impairs development of lung metastases.
D'Alterio C; Barbieri A; Portella L; Palma G; Polimeno M; Riccio A; Ieranò C; Franco R; Scognamiglio G; Bryce J; Luciano A; Rea D; Arra C; Scala S
Cancer Immunol Immunother; 2012 Oct; 61(10):1713-20. PubMed ID: 22399057
[TBL] [Abstract][Full Text] [Related]
23. Inhibitors of CXC chemokine receptor type 4: putative therapeutic approaches in inflammatory diseases.
Hummel S; Van Aken H; Zarbock A
Curr Opin Hematol; 2014 Jan; 21(1):29-36. PubMed ID: 24275689
[TBL] [Abstract][Full Text] [Related]
24. Molecular Pathways: Targeting the CXCR4-CXCL12 Axis--Untapped Potential in the Tumor Microenvironment.
Scala S
Clin Cancer Res; 2015 Oct; 21(19):4278-85. PubMed ID: 26199389
[TBL] [Abstract][Full Text] [Related]
25. Enhanced Anti-Leukemic Effects through Induction of Immunomodulating Microenvironment by Blocking CXCR4 and PD-L1 in an AML Mouse Model.
Hwang HS; Han AR; Lee JY; Park GS; Min WS; Kim HJ
Immunol Invest; 2019 Jan; 48(1):96-105. PubMed ID: 30204524
[TBL] [Abstract][Full Text] [Related]
26. Targeting CXCL12/CXCR4 Axis in Tumor Immunotherapy.
Zhou W; Guo S; Liu M; Burow ME; Wang G
Curr Med Chem; 2019; 26(17):3026-3041. PubMed ID: 28875842
[TBL] [Abstract][Full Text] [Related]
27. Macrophage Exclusion after Radiation Therapy (MERT): A First in Human Phase I/II Trial using a CXCR4 Inhibitor in Glioblastoma.
Thomas RP; Nagpal S; Iv M; Soltys SG; Bertrand S; Pelpola JS; Ball R; Yang J; Sundaram V; Lavezo J; Born D; Vogel H; Brown JM; Recht LD
Clin Cancer Res; 2019 Dec; 25(23):6948-6957. PubMed ID: 31537527
[TBL] [Abstract][Full Text] [Related]
28. Plerixafor: AMD 3100, AMD3100, JM 3100, SDZ SID 791.
Drugs R D; 2007; 8(2):113-9. PubMed ID: 17324009
[TBL] [Abstract][Full Text] [Related]
29. Bone-derived Nestin-positive mesenchymal stem cells improve cardiac function via recruiting cardiac endothelial cells after myocardial infarction.
Lu D; Liao Y; Zhu SH; Chen QC; Xie DM; Liao JJ; Feng X; Jiang MH; He W
Stem Cell Res Ther; 2019 Apr; 10(1):127. PubMed ID: 31029167
[TBL] [Abstract][Full Text] [Related]
30. Adipocytes enhance expression of osteoclast adhesion-related molecules through the CXCL12/CXCR4 signalling pathway.
Luo T; Liu H; Feng W; Liu D; Du J; Sun J; Wang W; Han X; Guo J; Amizuka N; Li X; Li M
Cell Prolif; 2017 Jun; 50(3):. PubMed ID: 27868262
[TBL] [Abstract][Full Text] [Related]
31. Blockade of CXCL12/CXCR4 axis ameliorates murine experimental colitis.
Mikami S; Nakase H; Yamamoto S; Takeda Y; Yoshino T; Kasahara K; Ueno S; Uza N; Oishi S; Fujii N; Nagasawa T; Chiba T
J Pharmacol Exp Ther; 2008 Nov; 327(2):383-92. PubMed ID: 18716065
[TBL] [Abstract][Full Text] [Related]
32. Effect of biodegradability on CXCR4 antagonism, transfection efficacy and antimetastatic activity of polymeric Plerixafor.
Li J; Oupický D
Biomaterials; 2014 Jul; 35(21):5572-9. PubMed ID: 24726746
[TBL] [Abstract][Full Text] [Related]
33. Recurrence of glioblastoma after radio-chemotherapy is associated with an angiogenic switch to the CXCL12-CXCR4 pathway.
Tabouret E; Tchoghandjian A; Denicolai E; Delfino C; Metellus P; Graillon T; Boucard C; Nanni I; Padovani L; Ouafik L; Figarella-Branger D; Chinot O
Oncotarget; 2015 May; 6(13):11664-75. PubMed ID: 25860928
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of CXCL12/CXCR4 suppresses pulmonary arterial smooth muscle cell proliferation and cell cycle progression via PI3K/Akt pathway under hypoxia.
Wei L; Zhang B; Cao W; Xing H; Yu X; Zhu D
J Recept Signal Transduct Res; 2015; 35(4):329-39. PubMed ID: 25421526
[TBL] [Abstract][Full Text] [Related]
35. Expression of chemokine CXCL12 and its receptor CXCR4 in folliculostellate (FS) cells of the rat anterior pituitary gland: the CXCL12/CXCR4 axis induces interconnection of FS cells.
Horiguchi K; Ilmiawati C; Fujiwara K; Tsukada T; Kikuchi M; Yashiro T
Endocrinology; 2012 Apr; 153(4):1717-24. PubMed ID: 22355073
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of the CXCL12/CXCR4 axis prevents periurethral collagen accumulation and lower urinary tract dysfunction in vivo.
Macoska JA; Wang Z; Virta J; Zacharias N; Bjorling DE
Prostate; 2019 May; 79(7):757-767. PubMed ID: 30811623
[TBL] [Abstract][Full Text] [Related]
37. CXCR7 is not obligatory for CXCL12-CXCR4-induced epithelial-mesenchymal transition in human ovarian cancer.
Zheng N; Liu W; Chen J; Li B; Liu J; Wang J; Gao Y; Shao J; Jia L
Mol Carcinog; 2019 Jan; 58(1):144-155. PubMed ID: 30259564
[TBL] [Abstract][Full Text] [Related]
38. Potential of CXCR4 antagonists for the treatment of metastatic lung cancer.
Burger JA; Stewart DJ; Wald O; Peled A
Expert Rev Anticancer Ther; 2011 Apr; 11(4):621-30. PubMed ID: 21504328
[TBL] [Abstract][Full Text] [Related]
39. Functional potentials of human hematopoietic progenitor cells are maintained by mesenchymal stromal cells and not impaired by plerixafor.
Ludwig A; Saffrich R; Eckstein V; Bruckner T; Wagner W; Ho AD; Wuchter P
Cytotherapy; 2014 Jan; 16(1):111-21. PubMed ID: 24119647
[TBL] [Abstract][Full Text] [Related]
40. Hypoxia and metastasis in an orthotopic cervix cancer xenograft model.
Chaudary N; Mujcic H; Wouters BG; Hill RP
Radiother Oncol; 2013 Sep; 108(3):506-10. PubMed ID: 23856487
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]